Mohsin Khan, Ph.D.

What I do

• Deal-making: source and assess differentiated assets, negotiate deals, and launch new companies (newcos)
• Asset strategy: guide assets end to end, from sourcing through pipeline development to value realization
• AI in BD: led the use of AI in asset sourcing and development for faster, smarter portfolio decisions
• Relationships: cultivate extensive investor and key opinion leader (KOL) networks

Representative TAs

Oncology · Immunology · Rheumatology · Dermatology · Metabolic & GI Disorders · Rare & Orphan Diseases

Previously

Strategy consulting leader at Booz Allen and Deloitte Life Sciences, advising institutions, startups and established companies on:

• Development strategy for therapeutic products
• Drug launch and commercialization
• Investment deployment and asset maturation